About curevac nv - CVAC
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
CVAC At a Glance
CureVac NV
Friedrich-Miescher-Strasse 15
Tübingen, Baden Wuerttemberg 72076
| Phone | 49-7071-9883-0 | Revenue | 578.90M | |
| Industry | Biotechnology | Net Income | 175.44M | |
| Sector | Health Technology | 2024 Sales Growth | 896.065% | |
| Fiscal Year-end | 12 / 2025 | Employees | 983 | |
| View SEC Filings |
CVAC Valuation
| P/E Current | 5.746 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 4.361 |
| Price to Sales Ratio | 1.322 |
| Price to Book Ratio | 1.061 |
| Price to Cash Flow Ratio | 6.94 |
| Enterprise Value to EBITDA | 1.261 |
| Enterprise Value to Sales | 0.53 |
| Total Debt to Enterprise Value | 0.132 |
CVAC Efficiency
| Revenue/Employee | 588,910.742 |
| Income Per Employee | 178,469.071 |
| Receivables Turnover | 19.872 |
| Total Asset Turnover | 0.68 |
CVAC Liquidity
| Current Ratio | 7.276 |
| Quick Ratio | 7.269 |
| Cash Ratio | 6.659 |
CVAC Profitability
| Gross Margin | 76.599 |
| Operating Margin | 37.778 |
| Pretax Margin | 35.667 |
| Net Margin | 30.305 |
| Return on Assets | 20.614 |
| Return on Equity | 27.149 |
| Return on Total Capital | 23.032 |
| Return on Invested Capital | 25.651 |
CVAC Capital Structure
| Total Debt to Total Equity | 5.594 |
| Total Debt to Total Capital | 5.297 |
| Total Debt to Total Assets | 4.853 |
| Long-Term Debt to Equity | 4.83 |
| Long-Term Debt to Total Capital | 4.574 |